Jan 04, 2023 4:01 pm EST Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 20, 2022 4:33 pm EST Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
Dec 19, 2022 7:00 am EST Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
Dec 15, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2022 10:00 am EST Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
Dec 02, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 23, 2022 8:00 am EST Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
Nov 08, 2022 4:01 pm EST Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress